Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yep.Morning Brighty.That’s when the Sa—ddo gang posting elsewhere got spiked.Never got over it as they sip their embittered tasting Latte’s in the S.Cafe they frequent daily even at weekends.What a waste of a life.D—rrminator even saying traders were bailing in the 2’s this morning which was clearly untrue.They dont allow Accuracy and reality to interfere with spewing out endless negativity and nonsense.What a waste of a life and yes they will miss out again on the opportunity the recent ridiculous low presented.Caio!!
Indeedy Latino. Nov 2017 sold some for 27.5p. But it was a real spike - A one day wonder! I wonder who bought!
Back in 2017 PYC had 5 days of huge gains when it announced a relatively small contract win (with a major pharma) in November 2017 the share price went from 1.3p to 4.2p in one day. It then climbed the next day from 5p to 10p. It then climbed the following day from 10p as high as 32p before closing at 17.1p. Anything is possible with PYC. See below. Good luck, Brighty
PYC chart covering Nov 28th 2017 to Dec 1st 2017 below
Date Open High Low Close Vol
Nov 30, 2017 10.51 32.00 9.50 17.125 49,900,790
Nov 29, 2017 5.00 10.00 3.77 9.50 78,119,582
Nov 28, 2017 1.30 4.2659 1.235 4.25 102,217,619
Remember this going to 25p a few years ago from 1.5p on Merck contract, so on the right news this rocket very far dyor
Yeah, 12" lol
well not seen this much interest for some time
small free float, being squeezed..
weekly poss 3.50 and monthly 8ema broken ,poss 4.00-4.20 would then be a poss next target IMHO
Actually a tad more than a mill by 9.am.Fabulous.Simething major afoot imo.
As another poster said about 2mths ago
PYC with £2mln value yet record and growing revenues of nearly £1mln for 2022 and cash to last 2 to 3 years ( company RNS) and working with cash rich oncology clients
PYC are one of only a few companies that can do mathematics modelling for cancer drug on the UK market
It makes PYC a clear target for a larger company
A tad under a million traded by 9.am.Definitely not the norm lol.
A few chunky ones as well.
Few silly Billy’s bailing early.Really?Onward and Upward is my take.!!
im anticipating this to go higher its broken the weekly 21ema 3.5 is next target
DT over on t'other site, cant even get my name right. If you cant even get a name right, then why should anyone listen to the opinion you have?
However, JM has alluded to trying to Have the Merck contracts penned at different times of the year, and not just the extension one in December ( normally near xmas ) i believe only 1 merck contract has been penned this year? So his hope of having contracts interspersed has not happened as yet?
I haven’t got an account over there as too many obsessive Beauts like D.The Dr-ll posting endless negativity cos they got burned some years back when the S.p here was way higher by allowing innate greed to totally cloud any trading sense.We’ve all been guilty of that over the years but they really have never been able to get over it bless..Basically has the intelligence and intellect of a challenged eight year old and that’s being generous lol.Fortunately Sinn Die from posting unending nonsense on this forum.They are totally embittered and blinkered to any discussion other than the company is a waste of space !!
Hi Kidlington
I don't know about Advfn sorry but if it's useful this is what was said in Dec 2021 from Merck
As has been the case in 2021, the board of Physiomics (the "Board") expects further contracts to be signed with Merck over the course of 2022.
Dr Jim Millen, CEO of Physiomics, said: "We're delighted that we continue to have a strong relationship with Merck and that our predictive modelling capabilities are, we believe, proving highly useful in the design of a number of their key clinical programs. In our view, there is no other company with Physiomics' experience in the field of DDR modelling and with every new project we further develop our capabilities in this field. These contracts provide a great platform for our work with Merck in 2022 and we expect further projects to be signed over the course of the full year."
Can someone point out over on the ADVFN Board that although Merck have a deal with Artios for DNA DDR, Merck also have also a deal with Physiomics for the same thing. Thou the money paid by Merck to the PYC deal is microscopic in comparison with Artios.
Typo-Buy out
I disagree with Kidlington on the possibility of a buy put.Some medium or large Pharma would probably only have to stump up approx £12 mill to take this in house -small change.And someone like Bicycle rather than one of the really large boys may see precision dosing and the expertise they would be purchasing as a field they could gain a foothold in and traction in internationally as it is applied across the medical landscape in multiple uses other than cancer treatments.Taking it on now would mean purchasing and advancing the tech very early doors for basically peanuts.All to play for imvho.
Thanks for that Kidlington
No royalties associated with CCS1477 ( as far as i am aware ) CellCentric have only 1 drug in their pipeline. Yes they have raised, but they aint going to buy PYC. That money raised is for the development of CCS1477 / Imobrodib. The only ones that would imho even think about buying is a larger pharma, that have oodles of projects going on.However they could still use PYC tech for a fraction of the cost of buying them out? So although its a nice idea of a buyout, its a non starter imho. Repeat biz is good, and will show other companies that savings can be made by using PYC. Prostate dosing tool is the potential company maker.
Have alot money to spend , I had a look at bicycle and they had about $250mln and a recent PYC client had raised $40mln and Cellcentric had $33mln
Maybe Baserite is correct ,why doesn't a client just buy Pyc as a whole company
Press ReleaseOctober 22, 2020
CellCentric raises $33m to broaden clinical trials of its first-in-class p300/CBP inhibitor, CCS1477